3-(2-piperidin-1-ylethoxy)-N-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide
C26H24N4O2S2 — CID 152614589
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-(2-piperidin-1-ylethoxy)-N-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide
3-(2-piperidin-1-ylethoxy)-N-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide (PubChem CID 152614589) has the molecular formula C26H24N4O2S2 and a molecular weight of 488.64 g/mol. Its IUPAC name is 3-(2-piperidin-1-ylethoxy)-N-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide.
Molecular Properties
| Compound Name | 3-(2-piperidin-1-ylethoxy)-N-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide |
|---|---|
| PubChem CID | 152614589 |
| Molecular Formula | C26H24N4O2S2 |
| Molecular Weight | 488.64 g/mol |
| Exact Mass | 488.13 |
| IUPAC Name | 3-(2-piperidin-1-ylethoxy)-N-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide |
| SMILES | O=C(Nc1nc2ccc3scnc3c2s1)c1cc2ccccc2cc1OCCN1CCCCC1 |
| InChI | InChI=1S/C26H24N4O2S2/c31-25(29-26-28-20-8-9-22-23(24(20)34-26)27-16-33-22)19-14-17-6-2-3-7-18(17)15-21(19)32-13-12-30-10-4-1-5-11-30/h2-3,6-9,14-16H,1,4-5,10-13H2,(H,28,29,31) |
| InChIKey | ZAFVLZTUBLNZGV-UHFFFAOYSA-N |
| XLogP | 6.18 |
| TPSA | 67.35 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 488.64 |
| LogP ≤ 5 | 6.18 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 152614589 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.